Retinal Dystrophy New Early Signs Detection Towards Vision Improvement: A Case Presentation

Villanueva A*, Marshall K2, Chung D3, Ayyagari R4, Maguire AM5, Bennett J2,5

1Retina Genomics Institute, Mérida, Yucatán, Mexico
2Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
3Spark Therapeutics, Philadelphia, PA, USA
4Shiley Eye Institute, University of California San Diego, 9415 Campus Point Drive, JRC 206, La Jolla, CA, USA
5Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Abstract

Introduction: This is a case presentation of inherited retina dystrophy type RPE65. We enhanced signs for early diagnosis in order to prevent vision loss as this condition has treatment now-a-days.

Method opted: Phenotype and genotype investigation resulted in RPE65 mutation, one sub-retinal injection was done in each eye.

Results: Vision is improved.

Discussion and conclusion: Early diagnosis is needed for LCA and retina dystrophies. This case presentation illustrated diagnosis is delayed due to the unknown early signs. Early signs are not detected by a specialist, even though for a mother is certain that vision is not normal for first month of life. There is treatment now and this may prevent loss of vision due to the degenerative nature of this condition, particularly as during first year of life treated patients manifest improved vision.

Keywords: Congenital; RPE65 mutation; Macular atrophy; RPE65 pathogenic variants

Case Report

A 2-month-old girl present with unusual wondering gaze. This characteristic wonder gaze is often presented during the day and more often during night. Her mother noticed she does not fix her vision and she is very happy with light, particularly during dusk. This child was taken to her paediatrician, neurologist, several ophthalmologists who said the child was within normal limits. Symptoms did not disappear, and few years passed. At the age of 5 years old this child was referred to us. We found other relevant features. She bumps very often into objects during first year of life. She developed fear of almost anything during dusk particularly.

During the examination, she presented with best corrected vision of central, fixes and remains steady OU. Pupils were sluggish. During fundus examination we found a very tiny mottling OU. Rest of ocular exam unremarkable. She does like to be near to her mother by 30 cm or less, she has no interaction with other children same age. Fundus pictures were taken with no relevant findings, no autofluorescence and ERG was not done. Other relevant medical history was negative.

We suspect inherited retina dystrophy Leber Congenital Amaurosis, we initiated phenotypal investigation of parents and request blood samples to complete with molecular test. We preformed PCR amplification of the coding sequence of RPE65 and sequenced. We wanted to rule out RPE65 as the possibility of treatment is now available. Platform used was WE sequenced ABI sequencer. We sequenced exons 4 and 5 of the RPE65 gene in this proband and detected both the c.311G>T and the c.370C>T mutations in the heterozygous state. Analysis of the parental samples showed that the sequence change c.311G>T was inherited from one parent while the sequence alteration c.370C>T was inherited from the other parent. The results of this segregation analysis confirm the bi-parental inheritance of these two changes. Therefore, the molecular diagnosis in this individual is consistent with the clinical diagnosis of RPE65 related Leber Congenital Amaurosis.

At the age of 7 years old, she presented with severe and fast deterioration of vision to hand motions at 10 cm over 8 months’ time, as natural history shows [1,2]. We proceed to AAV2-hRPE65v2 (voretigene neparvovec) (to deliver the human RPE65 cDNA) one subretinal injection [1,3-14]. After 1 month, she has improved her vision to 20/200 and about 100% functional.

Leber Congenital Amaurosis (LCA) occurs in 2 to 3 per 100,000 newborns reported in North America [11,15,16]. In Mexico, the National Institute of Statistics (INEGI), a Mexican statistics organization has not measured the incidence of this condition yet. Data in the only Mexican Inherited Retina Dystrophy registry shows there is apparently about 7 out of 100 registered patients with LCA diagnosis. We calculate there are probably 1200 cases in Mexico. LCA is one of the most common causes of blindness in children. Before 2017, LCA was among one of the retina degenerative diseases leading cause of irreversible blindness however now-a-days LCA type 2 has a cure [3,8,13,17-19].

The description of this disease was first made by Leber in 1989 [20-23], as:

1. Sluggish or near-absent pupillary reactions reflecting the severe retinal dysfunction.

*Corresponding author: Dr. Adda Villanueva, Retina Genomics Institute, Merida, Yucatan, Mexico and Spark Therapeutics, Philadelphia, PA, USA, Tel: 999-223-3623, E-mail: dr.villanueva@mejoravisionmd.com

Received September 23, 2018; Accepted October 20, 2018; Published October 23, 2018

Citation: Villanueva A, Marshall K, Chung D, Ayyagari R, Maguire AM, et al. (2018) Retinal Dystrophy New Early Signs Detection Towards Vision Improvement: A Case Presentation. J Mol Genet Med 12: 371 doi:10.4172/1747-0862.1000371

Copyright: ©2018 Villanueva A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
2. Nystagmus that is pendular or roving and present in all positions of gaze. However, this sign is late, once vision is lost.
3. High hyperopia (> 5 diopters), which is thought to result from impaired emmetropization (the ability of the eye to accommodate to visual stimuli) as a consequence of early-onset visual impairment.
4. Photophobia. However, this symptom is not present very often.
5. Keratoconus, a non-inflammatory, self-limiting axial ectasia of the central cornea.
6. Blindness or severe visual impairment presenting in infancy, frequently before age six months. Individuals with LCA usually do not achieve visual acuity better than 20/400 [17].
7. Extinguished or severely reduced scotopic and photopic electroretinogram (ERG).
8. The oculo-digital sign, characterized by poking, rubbing, and/or pressing of the eyes [23,24]. The oculo-digital sign has been claimed to be virtually pathognomonic for LCA; however, it can also be seen in other syndromic forms of severe vision impairment.
9. Family history typically consistent with autosomal recessive inheritance [15,18,21,25].

Diagnosis is not made soon enough to make an early diagnosis and follow up. Diagnosis should be made withing first 6 months of life since treatment could prevent loss of vision. Very early signs of LCA-RPE65 type are not known among physicians, as in this case.

Diagnosis usually takes 3-4 years even though parents notice some abnormalities of the child vision since the first month of life. Signs not previously described are:
A) Presence of staring at sun.
B) Unusual behaviour-related eye movement at dusk, child likes light (with marked change in behavior),
C) Mom feels her child is insecure, particularly at dusk.

Retinal findings

No retinal lesion is diagnostic of LCA or specific for certain genetic subtypes. Although fundus abnormalities are frequently present later in life, infants with LCA typically show either a normal fundus appearance or only subtle retinal pigment epithelial (RPE) granularity, retinal vessel attenuation and, uncommonly, various stages of macular atrophy.

The diagnosis of LCA in this case was established by clinical findings, parents’ allegations and observation about abnormalities as well as pupillary response.

Pathogenic variants in at least 17 genes are known to cause LCA: GUCY2D (LCA1), RPE65 (LCA2), SPATA7 (LCA3), AIPL1 (LCA4), LCA5 (LCA5), RPGRIP1 (LCA6), CRX (LCA7), CRB1 (LCA8), NMNAT1 (LCA9), CEP290 (LCA10), IMPDH1 (LCA11), RD3 (LCA12), RDH12 (LCA13), LRAT (LCA14), TULIP1 (LCA15), KCN13 (LCA16), and IQCB1 [26,27]. Together, pathogenic variants in these genes are estimated to account for more than half of all LCA diagnoses.

Of note, the three more specific retinal phenotypes that can be observed are [15,26,28-33].

1. Preserved para-arteriolar retinal pigment epithelium (PPRPE) in individuals with CRB1 pathogenic variants.
2. "Translucent RPE," white dots, and a peculiar star-shaped maculopathy in individuals with RPE65 pathogenic variants.
3. A progressive macular atrophic lesion presenting in infancy or later in some individuals. Because of its sharply defined borders, this lesion has been at times called a "macular coloboma." While it has been reported to occur with pathogenic variants in AIPL1 and CRB1, the correlation of this LCA phenotype is most prominent with pathogenic variants in NMNAT1 [30-33].

However, this case illustrates that none of the features previous described was present in this child. Findings described with "Translucent RPE," white dots, and a peculiar star-shaped maculopathy in individuals with RPE65 pathogenic variants, were not present at the very beginning in this patient, or otherwise fundus is within normal limits.

Discussion and Conclusion

Early diagnosis is needed for LCA and retina dystrophies. This case presentation illustrated diagnosis is delayed due to the unknown early signs. Early signs are not detected by a specialist, even though for a mother is certain that vision is not normal for first month of life.

Early diagnosis is needed for two reasons: 1) Vision develops during first decade of life. 2) There is treatment now and this may prevent loss of vision due to the degenerative nature of this condition, particularly as during first year of life treated patients manifest improved vision [33].

Awareness of early signs as in this case presentation:
A) Presence of staring at sun,
B) Unusual behaviour-related eye movement at dusk,
C) Child likes light (with marked change in behaviour) should be taken into account.

References
1. Jacobson SG (2011) Gene therapy for leber congenital amaurosis caused by RPE65 mutations. Arch Ophthalmol 130: 1-9.
2. Chung DC, Beretelsen M, Lorenz B, Pennesi ME, Leroy B, et al. (2018) The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol 9: 1-2.
3. Acland GM, Aguirre GD, Ray J (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28: 92-95.
4. Hollander A, Black A, Bennett J, Cremer S (2010) Lighting a candle in the dark: Advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 120: 3042-3053.
5. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. New Eng J Med 358: 2231-2239.
6. Jacobson SG, Alman TS, Cideciyan AV, Roman AJ, Sumaroka A, et al. (2009) Defining the residual vision in Leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 50: 2368-2375.
7. Maguire A, Simonelli F, Pierce E, Pugh EN, Mingozi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. New Eng J Med 358: 2240-2248.
8. Mathews F, Bareil C, Griffith J (1997) Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet 17: 139.
9. Simonelli F, Zivielo C, Testa F (2007) Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis Sci 48: 4284-4290.
10. Bennett J, Wellman J, Marshall KA, McCague S, Ashmari M, et al. (2016) Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: A follow-on phase 1 trial. Lancet 386: 661-672.

11. Hollander A, Black A, Bennett J, Cremers F (2010) Lighting a candle in the dark: Advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 120: 3042-3053.

12. Russell SR, Bennett J, Wellman J, Chung DC, Yu ZF, et al. (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. Lancet 1: 1-12.

13. Hollander A, Roepman R, Koenekoop RK, Cremers FPM (2008) Leber Congenital amaurosis: Genes, proteins and disease mechanisms. Prog Retin Eye Res 27: 391-419.

14. Hanein S, Perrault I, Gerber S, Tanguay G, Hamel C, et al. (2005) Leber congenital amaurosis Amarosa: Comprehensive survey of genetics heterogeneity. J Francais d'ophtalmol 28: 98.

15. Cremers FP, Hukr JA, Hollander A (2002) Molecular genetics of Leber congenital amaurosis. Hum Mol Genet 11: 1169-1176.

16. Hanein S, Perrault I, Gerber S, Tanguay G, Barbet F, et al. (2004) Leber congenital amaurosis: Comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy of molecular diagnosis. Hum Mut 23: 306-317.

17. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, et al. (2008) Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-Term Results of a Phase I Trial. Hum Gen Ther 19: 979-990.

18. Leber T (1869) Uber retinitis pigmentosa und angeborene amaurose. Graefes Arch Clin Exp Ophthalmol 15: 1-25.

19. Fazzi E, Signorini SG, Scelsa B, Bova SM, Lanzi G (2003) Leber's congenital amaurosis: An update. Eur J Paediatr Neurol 7: 13-22.

20. Aguirre GD, Baldwin V, Pearce-Kelling S, Narfström K, Ray K, et al. (1998) Congenital stationary night blindness in the dog: Common mutation in the RPE65 gene indicates founder effect. Mol Vol 1: 1-2.

21. Aguirre GD, Baldwin V, Pearce-Kelling S, Narfström K, Ray K, et al. (1998) Leber congenital amaurosis: Genes, proteins and disease mechanisms. Prog Retin Eye Res 27: 391-419.

22. Chiang AP, Beck JS, Yen HJ, Tayeh MK, Scheetz TE, et al. (2006) Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BB511). Proc Natl Acad Sci USA 103: 6287-6292.

23. Al-Khayer K, Hagstrom S, Pauer G, Zegarra H, Sears J, et al. (2004) Thirty-year follow-up of a patient with leber congenital amaurosis and novel RPE65 mutations. Am J Ophthalmol 137: 375-377.

24. Koenekoop RK, Lopez I, Hollander A, Allikmets R, Cremers FPM (2007) Genetic testing for retinal dystrophies and dysfunctions: Benefits, dilemmas and solutions. Clin Exp Ophthalmol 35: 473-485.

25. Majewski J, Wang Z, Lopez I, Humaid S, Huanan R, et al. (2011) A new ocular phenotype associated with an unexpected but known systemic disorder and mutation: Novel use of genomic diagnostics and exome sequencing. J Med Genet 48: 593-596.

26. Camuzat A, Rozet JM, Dohluf H, Gerber S, Perrault I, et al. (1996) Evidence of genetic heterogeneity of Leber's congenital amaurosis (LCA) and mapping of LCA1 to chromosome 17p13. Hum Genet 97: 798-801.

27. Perrault I, Rozet JM, Gerber S (1999) Leber congenital amaurosis. Mol Genet Metab 68: 200-208.

28. Falk MJ, Zhang Q, Nakamaru-Ogiso E, Kannabiran C, Fonseca-Kelly Z, et al. (2012) NMNAT1 mutations cause Leber congenital amaurosis. Nature Genet 44: 1040-1045.

29. Koenekoop RK, Loyer M, Dembinska O, Beneish R (2002) Visual improvement in Leber congenital amaurosis and the CRX genotype. Ophthal Genet 23: 49-59.

30. Perrault I, Hanein S, Sanjovichi X, Serre V, Nicouleau M, et al. (2012) Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat Genet 44: 975-977.

31. Chiang PW, Wang J, Chen Y, Fu Q, Zhong J, et al. (2012) Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet 44: 1-2.

32. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, et al. (2009) Vision 1 year after gene therapy for Leber congenital amaurosis. New Eng J Med 362: 725-727.

33. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, et al. (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial, to be formatted. Lancet 390: 849-860.